| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 63 | 2026 | 786 | 10.570 |
Why?
|
| Down Syndrome | 26 | 2025 | 200 | 6.960 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 143 | 2.700 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2025 | 89 | 2.390 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2023 | 555 | 2.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 1308 | 1.640 |
Why?
|
| Leukemia | 6 | 2023 | 354 | 1.390 |
Why?
|
| Child | 87 | 2026 | 25112 | 1.150 |
Why?
|
| Antineoplastic Agents | 9 | 2026 | 1754 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1233 | 0.920 |
Why?
|
| Philadelphia Chromosome | 3 | 2024 | 42 | 0.900 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 29 | 0.880 |
Why?
|
| Disease-Free Survival | 16 | 2024 | 902 | 0.880 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 2 | 0.830 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 26 | 0.820 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 116 | 0.810 |
Why?
|
| Methotrexate | 7 | 2025 | 312 | 0.780 |
Why?
|
| Child, Preschool | 41 | 2026 | 14375 | 0.760 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 132 | 0.750 |
Why?
|
| Humans | 111 | 2026 | 126134 | 0.750 |
Why?
|
| Prognosis | 24 | 2024 | 4697 | 0.730 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 170 | 0.670 |
Why?
|
| Penetrance | 1 | 2020 | 106 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1158 | 0.640 |
Why?
|
| Lymphoma | 1 | 2023 | 315 | 0.630 |
Why?
|
| Infant | 31 | 2026 | 12803 | 0.630 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 169 | 0.620 |
Why?
|
| Integrases | 1 | 2020 | 153 | 0.620 |
Why?
|
| Receptors, Cytokine | 4 | 2024 | 64 | 0.620 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2026 | 135 | 0.600 |
Why?
|
| Adolescent | 37 | 2026 | 19986 | 0.590 |
Why?
|
| Mycoses | 2 | 2021 | 114 | 0.560 |
Why?
|
| Gene Rearrangement | 4 | 2024 | 322 | 0.540 |
Why?
|
| Salvage Therapy | 1 | 2019 | 174 | 0.540 |
Why?
|
| Acute Disease | 8 | 2023 | 1039 | 0.520 |
Why?
|
| Young Adult | 22 | 2025 | 9635 | 0.500 |
Why?
|
| Male | 59 | 2026 | 62225 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 770 | 0.490 |
Why?
|
| Metabolome | 3 | 2025 | 318 | 0.470 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 514 | 0.460 |
Why?
|
| Female | 58 | 2026 | 68037 | 0.460 |
Why?
|
| Genome-Wide Association Study | 7 | 2025 | 1732 | 0.450 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 133 | 0.450 |
Why?
|
| Recurrence | 9 | 2024 | 1408 | 0.440 |
Why?
|
| Metabolomics | 3 | 2025 | 457 | 0.440 |
Why?
|
| Remission Induction | 2 | 2012 | 298 | 0.440 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2025 | 50 | 0.430 |
Why?
|
| Transcription Factors | 3 | 2020 | 2357 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2025 | 2752 | 0.420 |
Why?
|
| Self Report | 1 | 2017 | 533 | 0.420 |
Why?
|
| Mutation | 9 | 2023 | 5933 | 0.420 |
Why?
|
| Induction Chemotherapy | 2 | 2025 | 54 | 0.390 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1783 | 0.380 |
Why?
|
| Steroids | 1 | 2013 | 156 | 0.380 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 266 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2014 | 319 | 0.350 |
Why?
|
| Gene Deletion | 3 | 2021 | 769 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3260 | 0.340 |
Why?
|
| Treatment Failure | 1 | 2012 | 335 | 0.340 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 569 | 0.340 |
Why?
|
| DNA Methylation | 3 | 2021 | 1036 | 0.340 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2391 | 0.330 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 225 | 0.330 |
Why?
|
| Genomics | 5 | 2024 | 1577 | 0.310 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 5 | 0.300 |
Why?
|
| Dasatinib | 2 | 2020 | 48 | 0.300 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 297 | 0.280 |
Why?
|
| Histones | 1 | 2011 | 507 | 0.270 |
Why?
|
| Point Mutation | 1 | 2008 | 337 | 0.270 |
Why?
|
| Residence Characteristics | 2 | 2020 | 269 | 0.270 |
Why?
|
| Case-Control Studies | 9 | 2026 | 3307 | 0.250 |
Why?
|
| Mice | 12 | 2025 | 17619 | 0.250 |
Why?
|
| Neoplasms | 4 | 2022 | 2841 | 0.240 |
Why?
|
| Nondisjunction, Genetic | 1 | 2025 | 11 | 0.240 |
Why?
|
| Crossing Over, Genetic | 1 | 2025 | 52 | 0.230 |
Why?
|
| Acrylamides | 1 | 2025 | 24 | 0.230 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2025 | 19 | 0.230 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 70 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 294 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12393 | 0.230 |
Why?
|
| Leukapheresis | 1 | 2025 | 14 | 0.230 |
Why?
|
| Genotype | 6 | 2021 | 2604 | 0.230 |
Why?
|
| Osteosarcoma | 1 | 2008 | 259 | 0.230 |
Why?
|
| Trisomy | 1 | 2025 | 107 | 0.230 |
Why?
|
| Microfluidics | 1 | 2025 | 25 | 0.220 |
Why?
|
| Animals | 16 | 2025 | 33230 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 37 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2024 | 740 | 0.220 |
Why?
|
| Exome | 3 | 2022 | 1065 | 0.220 |
Why?
|
| Survival Rate | 7 | 2021 | 2055 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.210 |
Why?
|
| Mercaptopurine | 3 | 2019 | 72 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 51 | 0.210 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 15 | 0.210 |
Why?
|
| Piperidines | 1 | 2025 | 223 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 121 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 427 | 0.200 |
Why?
|
| Bone Marrow | 2 | 2022 | 304 | 0.200 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 47 | 0.200 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1901 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 130 | 0.190 |
Why?
|
| Immunoglobulins | 1 | 2023 | 157 | 0.190 |
Why?
|
| Risk Factors | 9 | 2025 | 10374 | 0.190 |
Why?
|
| Lipids | 1 | 2026 | 550 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 331 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 137 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2021 | 739 | 0.180 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 79 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3474 | 0.180 |
Why?
|
| Adult | 14 | 2025 | 30314 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 162 | 0.180 |
Why?
|
| Alleles | 3 | 2021 | 1611 | 0.180 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.170 |
Why?
|
| Retrospective Studies | 12 | 2024 | 16831 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 687 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 57 | 0.170 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Incidence | 6 | 2024 | 3193 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 512 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 147 | 0.160 |
Why?
|
| Leukocyte Count | 3 | 2025 | 246 | 0.160 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 18 | 0.160 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 26 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 74 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 79 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 260 | 0.150 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 295 | 0.150 |
Why?
|
| Cytokines | 1 | 2025 | 1317 | 0.150 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 20 | 0.150 |
Why?
|
| Karyotyping | 4 | 2015 | 313 | 0.150 |
Why?
|
| Social Class | 1 | 2020 | 198 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 541 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1344 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2021 | 356 | 0.150 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 28 | 0.150 |
Why?
|
| Diploidy | 2 | 2008 | 37 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 193 | 0.140 |
Why?
|
| Biomarkers | 3 | 2026 | 3149 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2021 | 770 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 5107 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8381 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2024 | 327 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 626 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 66 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2020 | 190 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2019 | 145 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2019 | 110 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 101 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2020 | 256 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1852 | 0.130 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 500 | 0.130 |
Why?
|
| Registries | 2 | 2022 | 1478 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 867 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 59 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 601 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 666 | 0.130 |
Why?
|
| Genome, Human | 2 | 2021 | 1284 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1107 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2020 | 542 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2021 | 765 | 0.120 |
Why?
|
| Cell Line | 3 | 2013 | 2570 | 0.120 |
Why?
|
| Base Sequence | 2 | 2011 | 2773 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2024 | 3422 | 0.120 |
Why?
|
| Risk | 2 | 2023 | 723 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 111 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 712 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 37 | 0.120 |
Why?
|
| Smad Proteins | 1 | 2015 | 42 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 322 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 746 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 753 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 258 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1803 | 0.110 |
Why?
|
| Dexamethasone | 3 | 2021 | 263 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1430 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2024 | 4894 | 0.110 |
Why?
|
| Texas | 5 | 2022 | 3536 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 1026 | 0.110 |
Why?
|
| Age Factors | 3 | 2021 | 2766 | 0.100 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 412 | 0.100 |
Why?
|
| Dendritic Cells | 2 | 2013 | 435 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2025 | 1840 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 872 | 0.100 |
Why?
|
| Cytosol | 1 | 2013 | 139 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 334 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 450 | 0.100 |
Why?
|
| Electronics | 2 | 2023 | 44 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 36 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 561 | 0.100 |
Why?
|
| Logistic Models | 3 | 2026 | 1739 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 415 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 656 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 143 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 931 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 336 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 127 | 0.090 |
Why?
|
| Cellulitis | 1 | 2011 | 61 | 0.090 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 423 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 272 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 722 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 415 | 0.080 |
Why?
|
| Immunophenotyping | 3 | 2019 | 331 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 603 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 289 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1239 | 0.080 |
Why?
|
| Nitriles | 2 | 2024 | 149 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 199 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 238 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1475 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 537 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 291 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 994 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 52 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 49 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 99 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 679 | 0.080 |
Why?
|
| Vincristine | 2 | 2021 | 193 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 523 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 241 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2023 | 758 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 62 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2024 | 405 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 582 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 317 | 0.070 |
Why?
|
| Gene Editing | 2 | 2021 | 197 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 729 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 642 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 1187 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 836 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 599 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2555 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 4517 | 0.060 |
Why?
|
| Meiosis | 1 | 2025 | 105 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2025 | 4472 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 93 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2025 | 46 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1294 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1490 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2012 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2008 | 825 | 0.050 |
Why?
|
| Cell Separation | 1 | 2025 | 219 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1706 | 0.050 |
Why?
|
| Leukocytes | 1 | 2025 | 203 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 197 | 0.050 |
Why?
|
| France | 1 | 2023 | 84 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 22 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 159 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 11 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 31 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 1739 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 40 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2176 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1131 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 662 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 455 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1011 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 313 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2328 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2021 | 34 | 0.040 |
Why?
|
| Entropy | 1 | 2021 | 29 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 6 | 0.040 |
Why?
|
| Transcriptome | 2 | 2019 | 1064 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 39 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 38 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1574 | 0.040 |
Why?
|
| United States | 3 | 2021 | 11187 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 349 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 33 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 28 | 0.040 |
Why?
|
| Sepsis | 1 | 2024 | 486 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 241 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 130 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 559 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 127 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 287 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 853 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 41 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 108 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 51 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3716 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 15 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 108 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 221 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 744 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 258 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 144 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 218 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 303 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2025 | 530 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 969 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3394 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 112 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 777 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4313 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 352 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 354 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 131 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 71 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 479 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 572 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 21 | 0.040 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 22 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 274 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 188 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 150 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 566 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1298 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 6178 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 607 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 64 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 21 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 575 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 42 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 175 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1262 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 615 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 276 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 392 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 425 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 840 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 287 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1179 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 829 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 857 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 677 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 565 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 770 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 278 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 172 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2014 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 136 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 122 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1639 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 528 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 29 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 808 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1381 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 95 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 60 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1942 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 722 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 510 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 74 | 0.020 |
Why?
|
| Epilepsy | 1 | 2020 | 846 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 133 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 200 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 1521 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 106 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 707 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1540 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4433 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1598 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 656 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 782 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2319 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 639 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 520 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 789 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1349 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1205 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2038 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1675 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 500 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1005 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2906 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2877 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2005 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 27402 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 20078 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 681 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2332 | 0.010 |
Why?
|